Photothermal Therapy and CD47 Blockade: Dual Immune Reprogramming in Oral Squamous Cell Carcinoma

Study Background and Research Question

Oral squamous cell carcinoma (OSCC) remains a major oncological challenge, accounting for approximately 90% of oral malignancies worldwide. Despite advances in surgery, radiotherapy, and chemotherapy, the five-year overall survival rate for OSCC patients ranges from 50% to 64% [source_type: paper][source_link: https://doi.org/10.1007/s00262-025-04281-z]. Recurrence is common, often attributed to immune evasion mechanisms and the restrictive tumor microenvironment. A key immune checkpoint in OSCC is CD47, a cell surface glycoprotein that delivers a 'don’t eat me' signal to macrophages through interaction with signal regulatory protein α (SIRPα), thereby suppressing phagocytic clearance of tumor cells. Although CD47 blockade has shown promise in preclinical immunotherapy, its efficacy in solid tumors like OSCC is limited by poor induction of pro-phagocytic signals and by the extracellular matrix (ECM) impeding macrophage infiltration [source_type: paper][source_link: https://doi.org/10.1007/s00262-025-04281-z].

Key Innovation from the Reference Study

The referenced study addresses these limitations by investigating the combined use of photothermal therapy (PTT) with CD47 blockade in OSCC. The central innovation lies in using PTT not only to induce direct tumor cell damage but also to stimulate immunogenic cell death (ICD), thereby enhancing calreticulin (CRT) exposure on tumor cells. CRT acts as an 'eat me' signal, promoting macrophage-mediated phagocytosis. Furthermore, PTT was found to remodel the tumor ECM, facilitating greater macrophage infiltration and amplifying the therapeutic impact of CD47 blockade [source_type: paper][source_link: https://doi.org/10.1007/s00262-025-04281-z]. This dual-action strategy represents a significant advance over either approach alone.

Methods and Experimental Design Insights

The authors utilized a combination of in vitro and in vivo models to dissect the synergy between PTT and CD47 blockade. In vitro, they assessed macrophage phagocytosis of tumor cells by flow cytometry, quantifying the enhancement provided by combined therapy. Immunogenic cell death was validated by measuring the release of ATP and high-mobility group protein B1 (HMGB1), as well as CRT exposure on tumor cell membranes. Confocal microscopy was employed to confirm the co-localization of CRT-expressing tumor cells and macrophages. In vivo, tumor-bearing mice received PTT, CD47 blockade, or both, with subsequent monitoring of tumor growth and analysis of ECM components at both the transcript and protein levels. Immunofluorescence staining enabled detailed mapping of macrophage infiltration into tumor tissue [source_type: paper][source_link: https://doi.org/10.1007/s00262-025-04281-z].

Protocol Parameters

• In vitro PTT assay | 60 seconds laser exposure | OSCC cell lines | Sufficient for inducing ICD and CRT exposure | paper [source_link: https://doi.org/10.1007/s00262-025-04281-z]
• ICD marker measurement (ATP/HMGB1 release) | Quantitative ELISA post-PTT | OSCC cultures | Validates immunogenic effects of PTT | paper [source_link: https://doi.org/10.1007/s00262-025-04281-z]
• CD47 antibody blockade | Established blocking concentrations | In vivo murine OSCC | Benchmarked against prior immunotherapy studies | paper [source_link: https://doi.org/10.1007/s00262-025-04281-z]
• Confocal imaging for CRT-macrophage co-localization | High-resolution fluorescence microscopy | Tumor sections post-treatment | Demonstrates mechanism of synergy | paper [source_link: https://doi.org/10.1007/s00262-025-04281-z]
• For photodynamic or photothermal therapy with Cardiogreen | 1000 μg/mL dye, 5 min incubation, 60 sec laser exposure | Human gingival fibroblast cells and OSCC models | Standardized to promote apoptosis and ICD | workflow_recommendation [source_link: https://www.apexbt.com/cardiogreen.html]

Core Findings and Why They Matter

The study's principal findings are twofold. First, PTT in combination with CD47 blockade significantly enhances macrophage-mediated phagocytosis of OSCC cells, both in vitro and in vivo, leading to more pronounced tumor growth inhibition relative to either treatment alone. Mechanistically, PTT induces ICD in tumor cells, marked by increased ATP and HMGB1 release and robust CRT exposure on the cell surface. Confocal microscopy confirmed that CRT-expressing tumor cells are preferentially co-localized with macrophages, validating the importance of the 'eat me' signal [source_type: paper][source_link: https://doi.org/10.1007/s00262-025-04281-z].

Second, PTT downregulates ECM components at both the transcript and protein levels, which correlates with increased infiltration of macrophages into tumor tissue. This remodeling of the tumor matrix is critical for overcoming the physical barrier that often limits immunotherapy efficacy in solid tumors. Together, these effects enable a dual mode of action: (1) providing a pro-phagocytic signal via CRT exposure and (2) facilitating macrophage access to tumor cells by loosening the ECM [source_type: paper][source_link: https://doi.org/10.1007/s00262-025-04281-z].

Comparison with Existing Internal Articles

Previous internal resources have established the utility of Cardiogreen (Indocyanine green) as a near-infrared fluorescent dye for vascular imaging, cardiac output measurement, and as a photosensitizer in photodynamic therapy workflows. For instance, Cardiogreen: Fluorescent Dye for Vascular Imaging and PDT summarizes its strong plasma protein binding and its ability to induce apoptosis via photodynamic mechanisms [source_type: workflow_recommendation][source_link: https://fk228.org/index.php?g=Wap&m=Article&a=detail&id=11190]. Similarly, Applied Workflows with Cardiogreen (Indocyanine Green) in Diagnostics and PDT details standardized protocols for apoptosis induction in photodynamic therapy, highlighting the reproducibility and high purity of APExBIO’s Cardiogreen in research settings [source_type: workflow_recommendation][source_link: https://eprinomectinsource.com/]. The present reference study expands on these foundations by demonstrating a new immunological dimension: PTT not only mediates direct tumor cell apoptosis (as in photodynamic therapy) but also plays a pivotal role in immune reprogramming, particularly in synergy with checkpoint blockade. This positions Cardiogreen and similar agents as integral tools for both diagnostic and immunotherapeutic workflows, bridging photodynamic effects and immune modulation.

Limitations and Transferability

While the study provides compelling evidence for the synergistic effects of PTT and CD47 blockade in preclinical OSCC models, several limitations warrant consideration. The efficacy and safety of this combination remain to be validated in clinical trials and in broader tumor types. Additionally, the depth of light penetration required for effective PTT may limit applicability to more superficial or accessible tumors. Variability in ECM composition across tumor microenvironments may also impact the generalizability of ECM remodeling effects. Finally, the use of specific photosensitizers, such as indocyanine green (ICG) analogues, must be optimized for each experimental context [source_type: paper][source_link: https://doi.org/10.1007/s00262-025-04281-z].

Why this cross-domain matters, maturity, and limitations

The convergence of photothermal and immunotherapeutic strategies illustrated in this study exemplifies a maturing paradigm in cancer therapy, where physical disruption (via PTT) is leveraged to unlock immune-mediated clearance. The translation of these findings from OSCC to other solid tumors will depend on further validation of immune and ECM responses in diverse microenvironments. The approach is promising but not yet standard-of-care, and clinical translation will require careful optimization of both the photosensitizer and the immunomodulatory agent.

Research Support Resources

For researchers aiming to replicate or extend these findings, Cardiogreen (Indocyanine Green) (SKU B8315) is available as a high-purity, water-soluble near-infrared dye suitable for both diagnostic imaging and as a photosensitizer in photothermal or photodynamic therapy protocols. Standard experimental conditions involve incubation at 1000 μg/mL for 5 minutes followed by 60 seconds of laser exposure to induce apoptosis—parameters aligned with recent literature and APExBIO workflow recommendations [source_type: product_spec][source_link: https://www.apexbt.com/cardiogreen.html]. These resources can facilitate robust and reproducible workflows for both vascular diagnostics and experimental cancer immunotherapy.